Literature DB >> 24392874

Astragalosides IV inhibits high glucose-induced cell apoptosis through HGF activation in cultured human tubular epithelial cells.

Qin Wang1, Xinghua Shao, Weijia Xu, Chaojun Qi, Leyi Gu, Zhaohui Ni, Shan Mou.   

Abstract

Astragaloside IV (ASI) in Radix Astragali is believed to be the active component. The study aims to investigate whether ASI inhibits tubular epithelial cells apoptosis induced by high glucose and its mechanisms. Tubular epithelial cells in this paper were isolated from human kidney. The cells apoptosis was detected by TUNEL and caspase 3 assay. The protein levels of HGF and TGF-β1 were measured by ELISA. The phospho-p38 production, ERK and JNK were determined by Western blot. ASI could inhibit cells apoptosis induced by high glucose (25 mmol/L) in dose-dependent and time-dependent manners. ASI also inhibited high glucose-induced expression of TGF-β1 and activation of p38 MAPK pathway at the protein level. Furthermore, ASI increased HGF production in human tubular epithelial cells. The ASI inhibition of tubular epithelial cells apoptosis and reduction of TGF-β1 expression induced by high glucose may represent a new treatment for diabetic kidney injury. The mechanism underlying this inhibitory effect may be related to the inhibition of p38 MAPK signaling pathway activation and HGF overproduction.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24392874     DOI: 10.3109/0886022X.2013.867798

Source DB:  PubMed          Journal:  Ren Fail        ISSN: 0886-022X            Impact factor:   2.606


  12 in total

Review 1.  Natural antioxidants in the treatment and prevention of diabetic nephropathy; a potential approach that warrants clinical trials.

Authors:  Noori Al-Waili; Hamza Al-Waili; Thia Al-Waili; Khelod Salom
Journal:  Redox Rep       Date:  2017-03-09       Impact factor: 4.412

2.  Astragaloside IV attenuates renal fibrosis through repressing epithelial-to-mesenchymal transition by inhibiting microRNA-192 expression: in vivo and in vitro studies.

Authors:  Yaochen Cao; Li Zhang; Yu Wang; Qingchun Fan; Yakun Cong
Journal:  Am J Transl Res       Date:  2019-08-15       Impact factor: 4.060

3.  Treatment with astragaloside IV reduced blood glucose, regulated blood lipids, and protected liver function in diabetic rats.

Authors:  Dong Han
Journal:  J Int Med Res       Date:  2021-03       Impact factor: 1.671

4.  Yi Qi Qing Re Gao formula ameliorates puromycin aminonucleoside-induced nephrosis by suppressing inflammation and apoptosis.

Authors:  Yumin Wen; Yongli Zhan; Huijie Liu; Tingting Zhao; Liping Yang; Haojun Zhang; Xi Dong; Ping Li
Journal:  BMC Complement Altern Med       Date:  2015-05-27       Impact factor: 3.659

5.  Astragaloside IV alleviates early brain injury following experimental subarachnoid hemorrhage in rats.

Authors:  Anwen Shao; Songxue Guo; Sheng Tu; Al-baadani Ammar; Junjia Tang; Yuan Hong; Haijian Wu; Jianmin Zhang
Journal:  Int J Med Sci       Date:  2014-08-08       Impact factor: 3.738

6.  A Network Pharmacology Approach to Uncover the Mechanisms of Shen-Qi-Di-Huang Decoction against Diabetic Nephropathy.

Authors:  Sha Di; Lin Han; Qing Wang; Xinkui Liu; Yingying Yang; Fan Li; Linhua Zhao; Xiaolin Tong
Journal:  Evid Based Complement Alternat Med       Date:  2018-11-01       Impact factor: 2.629

Review 7.  Mechanisms and Efficacy of Chinese Herbal Medicines in Chronic Kidney Disease.

Authors:  Mingming Zhao; Yi Yu; Rumeng Wang; Meiying Chang; Sijia Ma; Hua Qu; Yu Zhang
Journal:  Front Pharmacol       Date:  2021-03-29       Impact factor: 5.810

Review 8.  Review of Herbal Traditional Chinese Medicine for the Treatment of Diabetic Nephropathy.

Authors:  Guang-dong Sun; Chao-yuan Li; Wen-peng Cui; Qiao-yan Guo; Chang-qing Dong; Hong-bin Zou; Shu-jun Liu; Wen-peng Dong; Li-ning Miao
Journal:  J Diabetes Res       Date:  2015-11-15       Impact factor: 4.011

9.  Long read reference genome-free reconstruction of a full-length transcriptome from Astragalus membranaceus reveals transcript variants involved in bioactive compound biosynthesis.

Authors:  Jun Li; Yuka Harata-Lee; Matthew D Denton; Qianjin Feng; Judith R Rathjen; Zhipeng Qu; David L Adelson
Journal:  Cell Discov       Date:  2017-08-29       Impact factor: 10.849

10.  Astragaloside IV ameliorates early diabetic nephropathy by inhibition of MEK1/2-ERK1/2-RSK2 signaling in streptozotocin-induced diabetic mice.

Authors:  Gaofeng Song; Pengxun Han; Huili Sun; Mumin Shao; Xuewen Yu; Wenjing Wang; Dongtao Wang; Wuyong Yi; Na Ge; Shunmin Li; Tiegang Yi
Journal:  J Int Med Res       Date:  2018-06-13       Impact factor: 1.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.